|
|
|
|
| LEADER |
05918nma a2202077 u 4500 |
| 001 |
EB001992059 |
| 003 |
EBX01000000000000001154961 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9783036501802
|
| 020 |
|
|
|a books978-3-0365-0181-9
|
| 020 |
|
|
|a 9783036501819
|
| 100 |
1 |
|
|a Fanti, Stefano
|
| 245 |
0 |
0 |
|a Role of Medical Imaging in Cancers
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2021
|
| 300 |
|
|
|a 1 electronic resource (312 p.)
|
| 653 |
|
|
|a machine learning
|
| 653 |
|
|
|a 18F-FDG PET/CT
|
| 653 |
|
|
|a radiomics
|
| 653 |
|
|
|a diffuse large B-cell lymphoma
|
| 653 |
|
|
|a DCFPyL
|
| 653 |
|
|
|a dynamic 18F-FDG PET/CT
|
| 653 |
|
|
|a response assessment
|
| 653 |
|
|
|a empyema
|
| 653 |
|
|
|a perfusion
|
| 653 |
|
|
|a positron emission tomography
|
| 653 |
|
|
|a diffusion
|
| 653 |
|
|
|a noninvasive imaging
|
| 653 |
|
|
|a VCAM-1
|
| 653 |
|
|
|a imaging parameters
|
| 653 |
|
|
|a FDG-PET/CT
|
| 653 |
|
|
|a Radium-223
|
| 653 |
|
|
|a International Consensus Guidelines
|
| 653 |
|
|
|a Adoptive
|
| 653 |
|
|
|a EBV
|
| 653 |
|
|
|a pleural dissemination
|
| 653 |
|
|
|a breast
|
| 653 |
|
|
|a Deauville criteria
|
| 653 |
|
|
|a imaging
|
| 653 |
|
|
|a Hounsfield unit
|
| 653 |
|
|
|a meningioma
|
| 653 |
|
|
|a consensus
|
| 653 |
|
|
|a two-tissue compartment model
|
| 653 |
|
|
|a meta-analysis
|
| 653 |
|
|
|a pancreatic neoplasms
|
| 653 |
|
|
|a immunotherapy
|
| 653 |
|
|
|a concurrent chemoradiotherapy
|
| 653 |
|
|
|a intraductal papillary mucinous neoplasms
|
| 653 |
|
|
|a texture analysis
|
| 653 |
|
|
|a relapse
|
| 653 |
|
|
|a sdAbs
|
| 653 |
|
|
|a radionuclide therapy
|
| 653 |
|
|
|a guidelines
|
| 653 |
|
|
|a Computer-assisted diagnosis
|
| 653 |
|
|
|a recurrence
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a magnetic resonance imaging
|
| 653 |
|
|
|a somatostatin receptor
|
| 653 |
|
|
|a prostate-specific-antigen
|
| 653 |
|
|
|a receptor status
|
| 653 |
|
|
|a cystic tumor
|
| 653 |
|
|
|a spectral-CT
|
| 653 |
|
|
|a metastatic breast cancer
|
| 653 |
|
|
|a immune checkpoint inhibitors
|
| 653 |
|
|
|a PET/MRI
|
| 653 |
|
|
|a circulating miRNAs
|
| 653 |
|
|
|a prognosis
|
| 653 |
|
|
|a heat shock protein 70
|
| 653 |
|
|
|a molecular imaging
|
| 653 |
|
|
|a biomarker
|
| 653 |
|
|
|a triple negative breast cancer
|
| 653 |
|
|
|a soft tissue sarcoma (STS)
|
| 653 |
|
|
|a ovarian cancer
|
| 653 |
|
|
|a Yin Yang 1
|
| 653 |
|
|
|a PD-1
|
| 653 |
|
|
|a nuclear medicine
|
| 653 |
|
|
|a response to treatment
|
| 653 |
|
|
|a biochemical recurrence
|
| 653 |
|
|
|a head and neck cancer
|
| 653 |
|
|
|a HPV
|
| 653 |
|
|
|a overutilization
|
| 653 |
|
|
|a mantle cell lymphoma
|
| 653 |
|
|
|a pleural effusion
|
| 653 |
|
|
|a XOFIGO
|
| 653 |
|
|
|a circulating tumor cells
|
| 653 |
|
|
|a NSCLC
|
| 653 |
|
|
|a squamous cell carcinoma of the head and neck
|
| 653 |
|
|
|a targeted therapy
|
| 653 |
|
|
|a PERCIST
|
| 653 |
|
|
|a 18F-FACBC
|
| 653 |
|
|
|a CTLA-4 Antigen
|
| 653 |
|
|
|a DCFBC
|
| 653 |
|
|
|a CD8-Positive T-Lymphocytes
|
| 653 |
|
|
|a pazopanib
|
| 653 |
|
|
|a radiation therapy
|
| 653 |
|
|
|a follow up
|
| 653 |
|
|
|a Immunotherapy
|
| 653 |
|
|
|a 68Gallium-PSMA PET/CT
|
| 653 |
|
|
|a PET
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a urothelial carcinoma
|
| 653 |
|
|
|a diagnosis
|
| 653 |
|
|
|a Hodgkin lymphoma
|
| 653 |
|
|
|a MRI
|
| 653 |
|
|
|a Molecular imaging
|
| 653 |
|
|
|a miRNA expression
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a adipose tissue
|
| 653 |
|
|
|a precision oncology
|
| 653 |
|
|
|a review
|
| 653 |
|
|
|a PSMA-1007
|
| 653 |
|
|
|a radionuclide imaging
|
| 653 |
|
|
|a glioblastoma
|
| 653 |
|
|
|a staging
|
| 653 |
|
|
|a marker
|
| 653 |
|
|
|a SUV
|
| 653 |
|
|
|a epistemology
|
| 653 |
|
|
|a bladder cancer
|
| 653 |
|
|
|a PD-L1
|
| 653 |
|
|
|a single-photon emission computed tomography
|
| 653 |
|
|
|a locally advanced cervical cancer
|
| 653 |
|
|
|a castrate resistant prostate cancer
|
| 653 |
|
|
|a diagnostic imaging
|
| 653 |
|
|
|a SPECT imaging
|
| 653 |
|
|
|a SUVmax
|
| 653 |
|
|
|a neuroimaging
|
| 653 |
|
|
|a diffusion tensor imaging
|
| 653 |
|
|
|a breast cancer
|
| 653 |
|
|
|a PSA kinetics thresholds
|
| 653 |
|
|
|a PDAC
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a SPECT/CT
|
| 653 |
|
|
|a dynamic contrast-enhanced magnetic resonance imaging
|
| 653 |
|
|
|a positron-emission tomography
|
| 653 |
|
|
|a PET/CT
|
| 653 |
|
|
|a programmed cell death 1 receptor
|
| 653 |
|
|
|a survival
|
| 653 |
|
|
|a p16
|
| 653 |
|
|
|a malignant pleural mesothelioma
|
| 653 |
|
|
|a head and neck neoplasms
|
| 653 |
|
|
|a Mesothelin
|
| 653 |
|
|
|a Therapy response assessment
|
| 653 |
|
|
|a pathologic
|
| 653 |
|
|
|a computed tomography
|
| 653 |
|
|
|a diffusion kurtosis imaging
|
| 653 |
|
|
|a gold nanoparticle
|
| 653 |
|
|
|a optimal cutoff level
|
| 653 |
|
|
|a FDG
|
| 653 |
|
|
|a response to therapy
|
| 653 |
|
|
|a non-small-cell lung cancer
|
| 653 |
|
|
|a treatment response
|
| 653 |
|
|
|a upper tract urothelial carcinoma
|
| 653 |
|
|
|a PSMA
|
| 653 |
|
|
|a mCRPC
|
| 653 |
|
|
|a radiomic
|
| 653 |
|
|
|a prostate
|
| 653 |
|
|
|a radioactive tracers
|
| 653 |
|
|
|a neovascularization
|
| 653 |
|
|
|a PI-RADS
|
| 653 |
|
|
|a radiogenomics
|
| 653 |
|
|
|a diffusion-weighted imaging
|
| 700 |
1 |
|
|a Evangelista, Laura
|
| 700 |
1 |
|
|a Fanti, Stefano
|
| 700 |
1 |
|
|a Evangelista, Laura
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-0181-9
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/3480
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/68462
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 120
|
| 082 |
0 |
|
|a 333
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a undefined
|